ambrey-geneticsambry-geneticsbmi-healthcareBMIbrca-test-ukbrcabupacardio-dxcolordowndownloadfacebookforwardhalio-dxhca-healthcareHCAhearticon-burgericon-closeicon-githubicon-twitternanostringnuffield-healthnuffieldoncodnaoncomarkribbonskylinevideovitality coloricon-github
ProstateNext (14 genes) logo

Is ProstateNext the right test for you?

If several members of your family have had prostate and other cancers – or maybe you have had a diagnosis yourself, this test is all about early detection, prevention and tailored therapies.

It involves analysis of a 14 gene panel designed to provide more precise data to guide you about additional screening or treatments and/or eligibility for clinical trials.

To get this test you will first need a consultation with your clinician where you can ask if this is the most appropriate option for you, then you can either:

  • Buy it directly from this website (this cost may be covered by your medical insurance).
  • Access it through your treating hospital/private healthcare provider.

This test is only available to those aged 18 years or above.


Why?Close tab

Would more frequent screening help you?

This test can help your clinician decide at what age and how often you should have screening for prostate and other cancers

Lifestyle choices which could reduce your risk

There’s no proven prostate cancer prevention strategy, but you may reduce your risk of prostate cancer by making healthy choices, such as exercising and eating a healthy diet that is low in fat.

Possible treatment choices

Identifying which specific therapies could help you is another aspect of this test, which can identify if you may benefit from a new therapy called PARP inhibitor treatment.

It involves drugs which block an enzyme used by cancer cells to repair damage caused by chemotherapy to their DNA, but it doesn’t affect healthy cells. In effect, it causes tumour cells to die.

This test analyses 14 genes including BRCA1 and BRCA2 – if no mutations are found in these, this gives you and your clinician a clear indication that targeted PARP inhibitor treatment will help you.

Your family

This test can also indicate if other member of your family may have hereditary risk of developing prostate or other cancers – and therefore what steps they need to take for further screening or monitoring.

You can discuss this with your clinician, or if you would like to talk to one of our experts about the test, call us on +44 (0) 7495 981816


How?Close tab

What do I need to do?

It’s usually a simple ‘spit test’ – all we need is your saliva. You’ll receive a kit with clear instructions on giving your sample.


ProcessClose tab

Buying the test

Step 1:  There are two options:

  • Via your treating hospital/private healthcare provider (we have special arrangements with many healthcare providers to enable you to access this test, click here to see the list)
  • By clicking the ‘Buy direct now’ button above (the cost may be covered by your medical insurance – check your policy details)

Step 2: Collection of sample

We will liaise directly with your clinician and organise the collection of your sample and delivery to the laboratory.

Step 3: Analysis and reporting

Your sample will be analysed and a report will be generated, usually within four to five weeks of receipt of your sample in the laboratory.

Step 4: Results

Your clinician will receive the test report giving a clear indication of whether you are at risk of prostate cancer or if you have already been diagnosed, what steps you – and possibly other members of your family – need to take next.


CliniciansClose tab

Is ProstateNext the right test for your patient?

Since hereditary prostate cancer is not well understood or often recognised, you need clear results to guide treatment decisions for your patient. ProstateNext is a 14-gene panel which offers more precision to identify and manage hereditary prostate cancer.

When to consider testing

  • Early-onset prostate cancer (diagnosed <50 years of age)
  • Metastatic prostate cancer at any age
  • Multiple primary cancers in one person (e.g. prostate and male breast cancer)
  • Personal history of prostate cancer and >1 family members* with breast cancer (<50 years of age) and/or invasive ovarian cancer
  • Personal history of prostate cancer and >2 family members* with breast, pancreatic, or prostate cancer

* On the same side of the family

Mutation Distribution and Detection Rates*









* Excludes MUTYH carriers, APC p.l1307K, and CHEK2 p.l157T

Test Description

ProstateNext analyzes 14 genes (listed above). 13 genes (excluding EPCAM) are evaluated by next generation sequencing (NGS) or Sanger sequencing of all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. In addition, sequencing of the promoter region is performed for the following genes: MLH1 (c.-337 to c.-194), and MSH2 (c.-318 to c.-65). The inversion of coding exons 1-7 of the MSH2 gene and the BRCA2 Portuguese founder mutation, c.156_157insAlu (also known as 384insAlu) are detected by NGS and confirmed by PCR and agarose gel electrophoresis.

Clinically significant intronic findings beyond 5 base pairs are always reported. Intronic variants of unknown or unlikely clinical significance are not reported beyond 5 base pairs from the splice junction. Additional Sanger sequencing is performed for any regions missing or with insufficient read depth coverage for reliable heterozygous variant detection.

Reportable small insertions and deletions, potentially homozygous variants, variants in regions complicated by pseudogene interference, and single nucleotide variant calls not satisfying 100x depth of coverage and 40% het ratio thresholds are verified by Sanger sequencing.1  Gross deletion/duplication analysis is performed for the covered exons and untranslated regions of all 14 genes using read-depth from NGS data with confirmatory multiplex ligation-dependent probe amplification (MLPA) and/or targeted chromosomal microarray. If a deletion is detected in exons 13, 14, or 15 of PMS2, double stranded sequencing of the appropriate exon(s) of the pseudogene, PMS2CL, will be performed to determine if the deletion is located in the PMS2 gene or pseudogene.

1. Mu W, et al. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. J Mol Diagn. 2016. 18(6):923-932.

This test is provided by:

Ambry Genetics

Frequently asked questions

Do I need a doctor to authorise this test?
Yes, your doctor will need to provide the sample required for this test
Will my health insurance cover the cost of this test?
Many health insurance plans cover the cost of genetic testing – check with your provider to find out if it is in your policy.
How soon do I get my results?
Usually within four to five weeks of receipt of your sample in the laboratory
How accurate is the test?
Ambry follows advanced laboratory procedures and ensures quality control to deliver accurate results you can trust.